March 1st Week, 2026 Regulatory Events 🎯 The European Commission approved Incyte ’s retifanlimab (anti-PD-1) + carboplatin + paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal. (Ref 1) ❓ How do the outcomes of this regimen compare against the current SOC? 🎯 The US FDA approved Johnson & Johnson Innovative Medicine ’s teclistamab (BCMA-directed CD3 T-cell engager) + daratu

Highlights from the CHMP Jan 2026 Meeting are out! Indication Expansions 💊 Johnson & Johnson Innovative Medicine 's niraparib & abiraterone acetate co-formulation (Akeega; PARP x CYP17 inhibitor) is indicated with prednisone or prednisolone in combination with androgen deprivation therapy (ADT) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) and BRCA 1/2 mutations (germline and/or somatic) 💊 Incyte and Takeda 's ponatinib (I

May 3rd Week, 2025 Regulatory Events 🎯 Incyte and MacroGenics, Inc. ’s retifanlimab (anti-PD-1) + carboplatin + paclitaxel has been...